Abstract
Despite propylthiouracil (PTU) and methimazole (MMI) having been used for more than a half century to treat hyperthyroidism caused by Graves’ disease, controversy still exists in antithyroid drug (ATD) therapy because of their significant side effects. Reports of adverse events involving cutaneous reactions, vasculitis, agranulocytosis and hepatotoxicity have appeared. In Indonesia, PTU was still included in National Essential Drugs List to treat Graves’ disease in children. The aim of our study was to provide insights into adverse events that can be associated with ATD use. We reviewed adverse events associated with ATD therapy in pediatric patients with Graves’ disease from September 2009 to June 2012 at outpatient clinic, Cipto Mangunkusumo Hospital, Jakarta. We found 21 patients with Graves’ disease aged 3-to16 yr old, 5 male and 16 female. During this periode, 9 patients (43%) treated with an average daily dose of PTU, the rest with MMI (57%). Adverse events attributed to PTU use were seen in 2 patients. Liver dysfunction was observed in 1 patient, alanine aminotransferase, aspartate aminotransferase and blood bilirubin were increased. The second one, developed epistaxis and had 2 times relaps episodes of thyrotoxicosis and suggested to perform thyroidectomy procedure. Four of the patients treated with PTU switched to MMI because of increased ALT/AST. None of them required hospitalization. One patient treated with PTU had full remission after 5 years of therapy. There was no adverse event observed in patients treated with MMI. Our results suggested that PTU use in children need routine biochemical monitoring to prevent severe adverse events.
Highlights
Despite propylthiouracil (PTU) and methimazole (MMI) having been used for more than a half century to treat hyperthyroidism caused by Graves’ disease, controversy still exists in antithyroid drug (ATD) therapy because of their significant side effects
The aim of our study was to provide insights into adverse events that can be associated with ATD use
We reviewed adverse events associated with ATD therapy in pediatric patients with Graves’ disease from September 2009 to June 2012 at outpatient clinic, Cipto Mangunkusumo Hospital, Jakarta
Summary
Despite propylthiouracil (PTU) and methimazole (MMI) having been used for more than a half century to treat hyperthyroidism caused by Graves’ disease, controversy still exists in antithyroid drug (ATD) therapy because of their significant side effects. Adverse events related with propylthiouracil therapy of Graves’ Disease in children at Cipto Mangunkusumo Hospital Jakarta Novina Andriana1,2*, Aman B Pulungan2, Bambang Tridjaja2 From 7th APPES Biennial Scientific Meeting Nusa Dua, Bali.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.